Recruiting now—Ages 2 Years to 85 Years

Innovative Drug Delivery Nanophotonic Platform for Implementation of Sarcoma Therapy

Sponsor: Istituto Ortopedico Rizzoli · NCT06599957 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

Bone and Soft Tissue Tumors

Where it's running2 sites

2 international sites

Istituto Ortopedico Rizzoli-OSOTT
Bologna, Emilia-Romagna, Italy 40136
Recruiting now
- Toni Ibrahim, MD Oncologist(contact)+39 0516366199 [email protected]
IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
Meldola, Emilia-Romagna, Italy 47014
Recruiting now
- Alessandro De Vita, MD(contact)+39 0543739239 [email protected]

See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Patients eligible for the study will be male or female, with an age ranging from 0- to 85 years, undergoing surgery or biopsy for STSs or BSs including osteosarcomas.
* Included patients may have undergone or may be still in treatment with chemotherapy (also neo-adjuvant settings), targeted therapy, radiotherapy, or combination therapy.
* IRST will enroll only adult patients (age \&gt; 18 years).
* Signed informed consent from all subjects enrolled in the study. IOR patients will have to sign both the specific project Informed Consent and the IOR Biobank Informed consent.

Exclusion Criteria:

* Patients not affected by STSs or BSs will be excluded from the study, as well as patients with multiple primary tumors.

Updated 2025-09-22 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.